Adaptive Biotechnologies (ADPT) Set to Post Earnings on Wednesday

Adaptive Biotechnologies (NASDAQ:ADPT) is expected to be releasing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.0911) per share and revenue of $71.57 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The company had revenue of $71.55 million during the quarter, compared to analysts’ expectations of $65.44 million. During the same quarter in the previous year, the company earned ($0.17) EPS. The company’s revenue for the quarter was up 21.5% on a year-over-year basis. On average, analysts expect Adaptive Biotechnologies to post ($0.40) EPS for the current fiscal year and ($0.19) EPS for the next fiscal year.

Adaptive Biotechnologies Price Performance

ADPT opened at $27.66 on Wednesday. The stock’s 50-day moving average price is $26.22 and its 200 day moving average price is $19.47. Adaptive Biotechnologies has a 12-month low of $12.00 and a 12-month high of $30.74.

Analysts Set New Price Targets

A number of brokerages have issued reports on ADPT. Piper Sandler boosted their price target on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Thursday, October 15th. TD Cowen lifted their price objective on shares of Adaptive Biotechnologies from $28.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. Morgan Stanley upped their target price on shares of Adaptive Biotechnologies from $22.00 to $27.00 and gave the stock an “equal weight” rating in a research note on Monday, October 12th. Finally, The Goldman Sachs Group started coverage on shares of Adaptive Biotechnologies in a report on Tuesday, September 29th. They set a “buy” rating and a $35.00 target price on the stock. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.06.

Insiders Place Their Bets

In related news, COO Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock in a transaction on Monday, October 5th. The shares were sold at an average price of $29.19, for a total transaction of $346,806.39. Following the sale, the chief operating officer directly owned 377,802 shares in the company, valued at $11,028,040.38. This trade represents a 3.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chad Robins sold 321,324 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $25.08, for a total transaction of $8,058,805.92. Following the completion of the sale, the chief executive officer directly owned 2,180,518 shares of the company’s stock, valued at approximately $54,687,391.44. This trade represents a 12.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 1,016,419 shares of company stock worth $25,879,607. 5.70% of the stock is currently owned by company insiders.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and research tools. Based in Seattle, Washington, the company analyzes immune-cell receptors to help identify and measure disease, support drug development and improve understanding of immune responses.

Adaptive’s products include clonoSEQ, a clinical assay used to detect and monitor measurable residual disease in certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia.